Amneal Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.amneal.com

Earnings Score
Safety Score

Market Cap $2.26B
Debt $2.71B
Cash $118.42M
EV $4.86B
FCF $243.18M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$116.89M
EBIT	$249.33M
ROA	7%
FCF	$243.18M
Equity	-$109.27M
Growth Stability	1
PE	-19.38
PEG	5.54
PB	-20.73
P/FCF	9.31
P/S	0.81
Price/Cash	0.05
Debt/Equity	-24.79
Debt/FCF	11.14
Net Margins	-4%
Gross Margins	37%
Op. Margins	9%
Earnings CAGR	-1%
Sales Growth YoY	18%
Sales Growth QoQ	4%
Sales CAGR	18%
FCF CAGR	-3%
Equity CAGR	-1%
Earnings Stability	-0.15
Earnings Growth YoY	-68%

Earnings Growth QoQ	20K%
Earnings CAGR 5Y	-3%
Sales CAGR 5Y	9%
FCF CAGR 5Y	-6%
Equity CAGR 5Y	-8%
Earnings CAGR 3Y	11%
Sales CAGR 3Y	11%
FCF CAGR 3Y	64%
Equity CAGR 3Y	-13%
Market Cap	$2.26B
Revenue	$2.79B
Assets	$3.50B
Total Debt	$2.71B
Cash	$118.42M
Shares Outstanding	308.98M
EV	4.86B
Earnings Score	6%
Safety Score	55%
Working Capital	458.04M
Current Ratio	1.41
Gross Profit	$1.02B
Shares Growth 3y	16%
Equity Growth QoQ	17%
Equity Growth YoY	-646%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

SEC Filings

Direct access to Amneal Pharmaceuticals, Inc. (AMRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Amneal Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Amneal Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%

Stability -15%

loading chart...

Amneal Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Amneal Pharmaceuticals, Inc..

Years

Calculation mode

= $2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$243M	$236M	$230M	$224M	$217M	$211M	$205M	$200M	$194M	$189M	$184M	$1.8B
DCF		$215M	$190M	$168M	$148M	$131M	$116M	$103M	$91M	$80M	$71M	$708M
Value	$2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	0%	0%	-12%	-37%	3%	1%	-12%	-4%	-4%	-4%
ROA	-	-	-0%	-6%	2%	4%	-2%	6%	7%	7%
ROE	-	0%	-22%	-174%	20%	3%	-91%	-420%	107%	-

Bad Net Margins (-4.18%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	11.29	16.2	-58.95	8.84	14.23	142.61	8.53	11.14	11.14
Debt over Equity	-	579.61	3.02	7.73	8.26	7.52	8.93	128.82	-24.79	-24.79
Growth Stability	-	-	-	-	-	-	-	-	-	1

Bad Debt/FCF ratio (11.14)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (-24.79)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	2%	61%	-2%	23%	5%	6%	8%	17%	9%
Earnings YoY growth	-	-	-	200%	-111%	-85%	-3K%	-69%	39%	-3%
Equity YoY growth	-	-	33K%	-61%	-1%	6%	-19%	-93%	-646%	-8%
FCF YoY growth	-	-2K%	20%	-127%	-809%	-40%	-90%	2K%	-20%	-6%